Preimplantation Genetic Testing Market Expands with Rising IVF Success Rates and Genetic Screening Demand

The global Preimplantation Genetic Testing (PGT) market is entering a "Precision Embryology" era, projected to grow from USD 745.2 million in 2026 to USD 1.87 billion by 2036. According to the latest comprehensive market intelligence from Fact.MR, the industry is accelerating at a robust CAGR of 9.5%, driven by the rising average age of first-time parents and breakthroughs in Non-Invasive PGT (niPGT) technologies.

Get detailed market forecasts, competitive benchmarking, and pricing trends:
https://www.factmr.com/connectus/sample?flag=S&rep_id=292

As genomic sequencing becomes faster and more cost-effective, PGT has transitioned from a specialized niche to a standard protocol in modern fertility care. The market is currently being reshaped by Artificial Intelligence (AI) in Embryo Selection and the integration of Next-Generation Sequencing (NGS), allowing for the detection of a broader spectrum of monogenic disorders and chromosomal abnormalities with over 99% accuracy.

Expert Insight: The Shift Toward Non-Invasive Diagnostics

"We are moving past the 'biopsy-heavy' era of fertility treatment," says a lead life sciences analyst at Fact.MR. "In 2026, the real value lies in Non-Invasive Preimplantation Genetic Testing (niPGT). By analyzing the cell-free DNA found in the spent culture medium, we can now screen embryos without the physical risks of a traditional biopsy. By 2030, we expect niPGT to be the primary gateway for aneuploidy screening, significantly lowering the barrier for patients who were previously hesitant about the invasive nature of genetic testing."

Market Highlights & Quick Stats

Current Valuation (2026E): USD 745.2 Million
Projected Valuation (2036F): USD 1.87 Billion
Forecasted CAGR:5%
Dominant Technology: Next-Generation Sequencing (NGS) (holding ~45% share).
Lead Procedure: PGT-A (Aneuploidy Screening).
Key Consumer Demographic: Women aged 35+ seeking IVF treatments.
Major Growth Driver: Increasing prevalence of hereditary genetic conditions.

Key Market Drivers and Emerging Trends

Late-Stage Parenthood Trends: As the average age of conception rises globally, the risk of chromosomal abnormalities increases, making PGT a critical tool for improving live birth rates and reducing miscarriage risks.

AI-Driven Morphokinetics: New AI platforms are combining genetic data with time-lapse imaging of embryo development to predict implantation success with unprecedented precision.

Expansion of PGT-M (Monogenic): There is a surging demand for screening specific single-gene disorders (like cystic fibrosis or sickle cell anemia), particularly in regions with high consanguinity or known hereditary risks.

Technological Democratization: The plummeting cost of NGS-based kits is allowing smaller fertility clinics to offer in-house testing, reducing the turnaround time for results from weeks to days.

Featured Snippet: What is the primary driver for the Preimplantation Genetic Testing Market?

The primary driver for the preimplantation genetic testing market is the rising global demand for IVF procedures combined with the increasing average age of maternal conception. As chromosomal risks rise with age, PGT-specifically PGT-A (Aneuploidy Screening)-is essential for identifying healthy embryos, thereby increasing pregnancy success rates and decreasing miscarriage rates. This growth is further amplified by the shift toward Non-Invasive PGT (niPGT) and AI-enhanced embryo selection, which make genetic screening safer and more accurate for prospective parents.

Regional Insights

North America: The largest regional market, fueled by a high concentration of advanced fertility clinics, favorable insurance reimbursement landscapes in several U.S. states, and the early adoption of NGS technologies.

Asia-Pacific: The fastest-growing region (8% CAGR). China and India are witnessing an explosion in demand due to the expansion of medical tourism for fertility, rising disposable incomes, and government initiatives to address declining birth rates.

Europe: A leader in Ethical & Regulatory Standards. Countries like Spain and the UK remain global hubs for PGT research, with a strong focus on balancing clinical innovation with stringent bioethical guidelines.
Competitive Landscape

The market is characterized by a "Consolidation of Tech" where diagnostic giants are acquiring specialized genomics startups.

Leading innovators include:

Illumina, Inc. (Leader in NGS platforms)
Thermo Fisher Scientific Inc.
CooperSurgical, Inc. (The Cooper Companies)
Vitrolife AB
Agilent Technologies, Inc.
Natera, Inc.
PerkinElmer, Inc.
Fulgent Genetics

Frequently Asked Questions (FAQs)

Q1: What is the difference between PGT-A, PGT-M, and PGT-SR?

A:PGT-A screens for abnormal numbers of chromosomes (aneuploidy). PGT-M tests for specific single-gene (monogenic) disorders inherited from parents. PGT-SR tests for structural rearrangements (translocations) in chromosomes.

Q2: Is Non-Invasive PGT (niPGT) as accurate as a biopsy?

A: Clinical studies in 2026 show that niPGT is reaching parity with traditional biopsies for aneuploidy screening, offering a highly reliable, risk-free alternative for embryo selection.

Q3: How much does PGT increase IVF success rates?

A: While results vary, PGT can increase the live birth rate per transfer by up to 25-30% in patients over the age of 35 by ensuring only chromosomally normal embryos are used.

Q4: Can PGT detect all genetic diseases?

A: No. PGT can only screen for conditions that have been specifically identified in the parents' genetic profile (for PGT-M) or major chromosomal imbalances (for PGT-A). It does not guarantee a "perfect" baby but significantly reduces known risks.

Full Report: Unlock 360° insights for strategic decision making and investment planning-

https://www.factmr.com/checkout/292

To View Related Report:

Genetic Beauty Market https://www.factmr.com/report/genetic-beauty-market

Genetic Analyzer Systems Market https://www.factmr.com/report/4695/genetic-analyzer-systems-market

Genetic Disorder Therapeutics Market https://www.factmr.com/report/2698/genetic-disorder-therapeutics-market

Genetic Testing Panels Market https://www.factmr.com/report/2820/genetic-testing-panels-market

- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

About Fact.MR
Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

This release was published on openPR.